Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Zhejiang University Future Capital-backed cancer and inflammatory disease drug developer has now raised more than $260m in under two years.

The SK Holdings, China Life and Legend Holdings-backed cancer and inflammatory disease drug developer has now raised more than $260m in under two years.

University of Birmingham‘s infectious disease reagent producer Native Antigen Company has been acquired in a deal enabling Mercia Asset Management to exit.

General Atlantic led a $75m series D round for Doctor on Demand, a virtual care provider with shareholders including GV, Qualcomm Ventures and Dignify Health.

Nikon was among the investors that helped the eye disease treatment developer close a round that pushed its overall funding to $24m.

Optum Ventures helped the prescription fulfilment platform push its total funding to more than $39m, with the cash to fund product development.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

VillageMD is set to receive a total of $1bn in equity and convertible debt financing from Walgreens Boots Alliance over the next three years, giving the corporate a 30% stake.

Chalmers Ventures head of startups Stina Linge will leave on September 2 to head up Lipidor's animal health products unit Emollivet.